MedTrace Logo

Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer

NCT00096304 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2018-04-10

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy, such as epirubicin and docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of epirubicin when given with docetaxel in treating patients with metastatic prostate cancer.

Conditions

Interventions

DRUG

docetaxel

DRUG

epirubicin hydrochloride

Sponsors & Collaborators

  • Medical University of South Carolina

    lead OTHER

Principal Investigators

  • Gustavo Leone · Medical University of South Carolina, Hollings Cancer Center

  • Andrew S. Kraft, MD · Medical University of South Carolina

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-08
Primary Completion
2006-09-06
Completion
2007-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00096304 on ClinicalTrials.gov